3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
15
Terminated
4
Recruiting
2
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Other hematologic neoplasm
2
Myeloid
2
Lymphoid
2
Conditions
Hematologic Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Leukemia, Myeloid, Acute
3
beta-Thalassemia
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Graft vs Host Disease
2
Anemia, Refractory, with Excess of Blasts
2
Virus Diseases
1
Thalassemia
1
Primary Myelofibrosis
1
Non-Malignant Neoplasm
1
Neurofibromatosis 1
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, B-Cell
1
Influenza, Human
1
Fanconi Anemia
1
Cytopenia
1
Chromosome Aberrations
1
Chromosome 7, monosomy
1
Anemia, Sickle Cell
1
Interventions
Cyclophosphamide
13
pembrolizumab
8
Brentuximab Vedotin
8
fludarabine
7
Nivolumab
7
Whole-Body Irradiation
6
Specimen Handling
6
Mycophenolic Acid
6
Gemcitabine
6
Etoposide
6
Doxorubicin
6
Dacarbazine
6
fludarabine phosphate
5
Vinblastine
5
Melphalan
5
Granulocyte Colony-Stimulating Factor
5
Filgrastim
5
Dexamethasone
5
Stem Cell Transplantation
4
Cytarabine
4
Vinorelbine
3
Tacrolimus
3
Magnetic Resonance Spectroscopy
3
Cyclosporine
3
Carmustine
3
Blood Specimen Collection
3
thymoglobulin
2
polatuzumab vedotin
2
pegylated granulocyte colony-stimulating factor
2
pegfilgrastim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Hodgkin Disease
×
thymoglobulin
×
Clear all
NCT04888741
2026-05-05
MoTD
University of Birmingham
Phase 2
Recruiting
400 enrolled
NCT03852407
2022-10-12
HLA
University of Liege
Phase 2
Recruiting
114 enrolled